- binx FDA-cleared platform already impacting human health-poised to transform care for millions
binx health, the pioneer in anywhere, anytime testing for women's health, today announced the first real-world use of the binx io platform, delivering same-visit diagnosis and treatment for chlamydia (CT) and gonorrhea (NG)-the two most tested-for sexually transmitted infections (STIs) globally. The World Health Organization (WHO) has previously indicated that the lack of reliable, low-cost, point-of-care tests that enable diagnosis and treatment in a single visit represents a major barrier to sexually transmitted infection (STI) control and prevention. With the company's recent CE Mark in Europe and FDA 510(k) clearance for rapid CT/NG testing, binx health is the first company to remove this barrier.
Under an Innovate UK SBRI grant, and in collaboration with three NHS Trusts and the Applied Diagnostic Research and Evaluation Unit at St. Georges University of London (SGUL), the binx io platform is now being used by clinicians to diagnose patients who otherwise would have faced up to several days of delay between infection identification and treatment.
Dr. Emily Mabonga, a clinical consultant from the Lewisham and Greenwich NHS Trust said, "So far, we have tested about 90 patients, have had 17 CT and two NG positives and were able to provide the right antibiotic in a single visit. British Association of Sexual Health and HIV quality standards suggest treatment within three weeks of testing. We can now provide the right antibiotic in one visit. This is game-changing for us."
"We are thrilled to see these results from real-world settings benefiting the first patients ever,"
